The relationship between plasma levels of pyridostigmine to clinical evaluation of muscle power was examined in nine patients with myasthenia gravis during treatment with pyridostigmine in doses of 60 to 1040 mg daily. Five of the nine subjects demonstrated a trend towards a positive correlation, but in only two of them was this statistically significant at p < 005. In addition, the presence or absence of a possible correlation between muscle power and plasma concentration was not related to the duration of the disease, additional prednisolone therapy or thymectomy.
Although anti-cholinesterases have been used in the treatment of myasthenia gravis since 1935, only recently has a reliable method been developed for measuring plasma concentrations of those drugsmost commonly used.' 2The present study was undertaken to examine the relationship between plasma levels of pyridostigmine and a global clinical evaluation of muscle power and fatigability such as could be carried out during an outpatient consultation. The discovery of a positive correlation between a global assessment of muscle power and plasma levels of pyridostigmine would be a valuable aid in optimising dosage schedules in individual patients.
Patients and methods
Two male and seven female patients between the ages of 19 and 58 years with histories of myasthenia gravis of 2 to 22 years duration were studied. Five of them had had thymectomies and three were being treated with prednisolone on alternate days. Histological examination of the thymus glands which were removed showed hyperplasia in four and thymoma in the fifth. The total daily dose of pyridostigmine ranged from 60-1080 mg. A diagnosis of myasthenia gravis was made if two of the following criteria were fulfilled: (a) a characteristic electromyographic response,3 (b) a positive edrophonium test,4 (c) an excess over normal of autoantibody directed against human skeletal muscle acetyl choline receptors. Some tests were not useful in some patients because they registered no change or no fatigue. However the importance in using all the subtests became clear when we noted that some functions fatigued maximally at different times from others. For example, in one subject the vital capacity might be at its lowest mid-morning, whereas walking 75 yards (68 m) was slowest in the evening and the arms fatigued most rapidly at noon. Nevertheless there was a tendency for good performances and poor performances to segregate so that the cumulative picture measured by the mean rank and mean scale scores was more representative of the subject's status than any single function. No single test correlated with plasma pyridostigmine concentration more closely than the global assessment. Diurnal variation in global scores for muscle strength was observed in all subjects except No 7 (table 4) and only one (No 8) was stronger in the afternoon than in the morning. This corresponds well with the patients' subjective observations. In only two subjects (2 and 6) was greater average muscle fatigue associated with higher average levels of plasma pyridostigmine. Subject 6 also showed a negative correlation p < 0-1 between muscle strength and plasma pyridostigmine plotted individually (fig 2) . One possible explanation for this observation is that this patient was receiving excessive medication. She was, however, particularly difficult to assess as her myasthenic disease included her extraocular muscles whereas her limb symptoms were thought to be functional.
Discussion
Studies of blood levels in myasthenia gravis are required since alteration of doses of oral anticholinesterases depends largely on the patient's own subjective response. The edrophonium test4 to determine optimal dosage is frequently difficult to interpret because the effect varies at different times Davison, Hyman, 
